Search for content, post, videos

AlgoDx announces FDA acceptance of De Novo application

The US Food and Drug Administration has accepted for review the company’s De Novo application for NAVOYÒ Sepsis, a clinical decision support software intended to assist healthcare providers at intensive care units (ICU) with predicting sepsis in adult ICU patients. "We are proud to announce th
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.